ARR increased 31% year-over-year to $811 million Q4 revenue increased 32% year-over-year to $196.3 million Q4 net cash provided by operating activities was $18.1 million, representing 9% of revenueSANTA CLARA, Calif., March 11, 2026 (GLOBE NEWSWIRE) — Netskope, Inc. (NASDAQ:NTSK) a leader in modern security and networking for the cloud and AI era, today announced financial results for the fourth quarter and fiscal year 2026, ended January 31, 2026. “We closed fiscal 2026 on a strong note, delivering record net new ARR in Q4 and achieving our first full year of positive free cash flow,” said Sanjay Beri, CEO of Netskope. “The AI Supercycle is here, demanding a new standard for high-performance security and networking. We believe the next decade will be defined by an intelligent edge. Our Netskope One platform combined with our...

Reported Promising Data for TN-201 and TN-401 Gene Therapies in Fourth Quarter of 2025; Additional Data Readouts and Pursuit of Regulatory Alignment for Each Program Planned in 2026 New Research Supports TN-301’s Potential in Multiple Indications; Presented Preclinical Data for TN-301 in Duchenne Muscular Dystrophy Model Entered into Multi-Target Research Collaboration with Alnylam Pharmaceuticals December Financing with Net Proceeds of $55.8M and Anticipated Upfront Payment Extend Cash Runway into Second Half of 2027 SOUTH SAN FRANCISCO, Calif., March 11, 2026 (GLOBE NEWSWIRE) — Tenaya Therapeutics, Inc. (NASDAQ: TNYA), a clinical-stage biotechnology company with a mission to discover, develop and deliver potentially curative therapies that address the underlying causes of heart disease, today announced financial results for the...

PLN-101095 Phase 1 data showed deep and durable ongoing responses in checkpoint inhibitor refractory solid tumors PLN-101095 accelerated development plan underway with initiation of Phase 1b indication expansion trial SOUTH SAN FRANCISCO, Calif., March 11, 2026 (GLOBE NEWSWIRE) — Pliant Therapeutics, Inc. (Nasdaq: PLRX), a clinical-stage biotechnology company focused on the discovery and development of integrin-based therapeutics, today provided a corporate update and reported fourth quarter 2025 financial results. “We ended 2025 with encouraging data from our lead oncology program in ICI-refractory patients, an area of unmet medical need, that informed the initiation of our accelerated development plan for PLN-101095,” said Bernard Coulie, M.D., Ph.D., President and Chief Executive Officer of Pliant. “In addition to oncology and...

CHICAGO, March 11, 2026 (GLOBE NEWSWIRE) — Oil-Dri Corporation of America (NYSE: ODC), producer and marketer of sorbent mineral products, today announced results for its second quarter and first six- months of fiscal year 2026.  Second Quarter Year to Date(in thousands, except per share amounts) Ended January 31, Ended January 31,  2026 2025 Change 2026 2025 ChangeConsolidated Results            Net Sales $ 117,737 $ 116,914 1 % $ 238,223 $ 244,859 (3)%Income from Operations * $ 15,693 $ 17,482 (10)% $ 32,647 $ 38,672 (16)%Net Income $ 12,569 $ 12,921 (3)% $ 28,025 $ 29,297 (4)%EBITDA † $ 21,735 $ 22,216 (2)% $ 45,376 $ 48,383 (6)%Diluted EPS – Common $ 0.87 $ 0.89 (2)% $ 1.93 $ 2.01 (4)%Business to Business            Net Sales $ 41,977 $ 43,416 (3)% $ 86,263 $ 91,831 (6)%Segment Operating...

– Base biologic matrix NXT-41 submitted to FDA; on track for anticipated FDA clearance in second half of 2026 and full NXT-41x clearance in 1H27 – – $44.4 million in cash and escrowed proceeds at year-end – – Conference call today at 5:00 p.m. ET / 2:00 p.m. PT – GAITHERSBURG, Md., March 11, 2026 (GLOBE NEWSWIRE) — Elutia Inc. (Nasdaq: ELUT) (“Elutia” or the “Company”), a pioneer in drug-eluting biomatrix technologies, today provided a business update and financial results for the fourth quarter and full year ended December 31, 2025. Business Highlights:NXT-41x Development Program On Track: Elutia continues to advance development of NXT-41x, a next-generation antibiotic-eluting biomatrix for plastic and reconstructive surgery. The Company has submitted the 510(k) application for the base biologic matrix, NXT-41, to FDA and anticipates...

     Q4 revenue of $38.9 million, total revenue of $70.4 million for the fiscal year ended December 31, 2025 Ended year with $78.2 million in cash, cash equivalents and short-term investments, runway through 2027 Completed $37.8 million Technology Transfer Agreement with Merck REDWOOD CITY, Calif., March 11, 2026 (GLOBE NEWSWIRE) — Codexis, Inc. (NASDAQ: CDXS), a leading provider of enzymatic solutions for efficient and scalable manufacturing of complex therapeutics, today announced financial results for the fourth quarter and year ended December 31, 2025, and provided a business update. “Throughout 2025, we made significant strides in demonstrating the importance of our ECO Synthesis® Manufacturing Platform to customers in the RNAi industry. We’ve secured multiple contracts with leading pharma, high growth biotech, and top tier...

CALGARY, Alberta, March 11, 2026 (GLOBE NEWSWIRE) — Freehold Royalties Ltd. (Freehold or the Company) (TSX:FRU) announces fourth quarter and year-end results for the period ended December 31, 2025. 2025 HighlightsCompleted the previously announced termination of the long-standing management agreement with Rife Management Ltd. (formerly Rife Resources Management Ltd.). Achieved record annual production of 16,294 boe/d, a 9% increase from 2024; Total annual crude oil and natural gas liquids production of 10,730 boe/d(1), a 12% increase from 2024; Generated total revenue of $313 million; Bonus and leasing revenue contributed $8 million, an increase from $3 million in 2024; Delivered $235 million in funds from operations ($1.43/share),(2)(4) a 2% increase from 2024; Returned $177 million ($1.08/share)(3) to shareholders through monthly...

FORT WORTH, Texas, March 11, 2026 (GLOBE NEWSWIRE) — HighPeak Energy, Inc. (“HighPeak” or the “Company”) (NASDAQ: HPK) today announced financial and operating results for the quarter and year ended December 31, 2025. In addition, HighPeak provided its 2026 guidance and capital budget, as approved by its Board of Directors. A statement from our President and CEO, Michael Hollis, “In light of the current geopolitical uncertainty and commodity price volatility, we are taking a disciplined and measured approach to 2026. Our priority is clear: protect profitability and maximize free cash flow, not chase production volumes. Our top financial objective is strengthening the balance sheet. Any incremental free cash flow generated in a stronger commodity price environment will be directed toward accelerating debt reduction. To strengthen...

MITCHEL FIELD, N.Y., March 11, 2026 (GLOBE NEWSWIRE) — Frequency Electronics, Inc. (“FEI” or the “Company”) (NASDAQ-FEIM) is pleased to announce its financial results for the third quarter and fiscal year 2026. Revenue for the three and nine months ended January 31, 2026, was approximately $16.9 million and $47.8 million, respectively, compared to $18.9 million and $49.8 million, respectively, reported for the same period of fiscal year 2025. Operating income for the three and nine months ended January 31, 2026 was $1.3 million and $3.3 million, respectively, compared to $3.5 million and $8.5 million, respectively, reported for the same period of the previous fiscal year. Net Income from operations for the three and nine months ended January 31, 2026, was $1.6 million or $0.16 per diluted share and $4.0 million or $0.41 per diluted...

2025 full-year resultsRevenue: €786.4 million, down 3.5% at CER1 and like-for-like2, mainly due to the fall in activity in France Profitability: restated EBITDA margin3 of 12.0% (at the high end of the adjusted range communicated in December) Net Income: loss of €112.7 million, which includes a non-recurring impairment of €86 million Free cash flow: in positive territory at €19.2 million Indebtedness: net debt/EBITDA ratio of 4.0x, below the ceiling of 4.8x set in December 2025 under the waiver obtained by the Group from its lenders.2026Significant negative impact expected from the situation in Raleigh on revenue, profitability, cash generation and group indebtedness with a probable risk of covenant breach on June 30, 2026 No dividend distribution in respect of the 2025 fiscal year Continuation of the transformation plan and strategic...